-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: June 2011
Five things you need to know about the state of the industry
What is the state of the biotechnology industry? To find out where the it stands and what strategies you need to survive, read Ernst & Young’s 25th annual industry report, Beyond borders: global biotechnology report 2011, that was released during a super session at the 2011 BIO International Convention. What were the industry’s profits last year? What kind of companies received funding? How should you engage the regulators? What new competencies do you need to Read More >
Evolution of Biotech Industry is a Constant
Healthcare being delivered by smartphone, homes containing treatment capabilities now only found in hospitals, groundbreaking innovations rising from the confluence of technology and science. Change is constant in the biotech industry and few industry experts know its evolution better than Steven Burrill. Burrill, CEO of Burrill and Company, presented his 25th anniversary annual report on the state of the biotech industry Biotech 2011-Life Sciences: Looking Back to See Ahead at the 2011 BIO International Convention Read More >
Biologics & Biosimilars: What is the Science Telling Us?
Panelists from the varied backgrounds of academia, business and regulation agreed on the highest scientific standards of biosimilar regulation. Each panelist emphasized the need for the most stringent of standards in order to ensure patient safety and efficacy within the emerging biosimilars market. As Brian Liang, Executive Director of the Institute of Health Law Studies at California Western School of Law, summed it up, “the need in biosimilars is to focus on science, not cost. These are Read More >
Biotech Business: Wait Our Model Isn’t Dead
Life sciences company and investment executives debated the current and future viability of the industry model for startup companies, given the tumultuous economic waters it traversed during the so-called Great Recession of 2008-2009. The aptly-named panel (“Wait, Our Model Isn’t Dead! We Just Need to Evolve”) appraised those lean times for biotech in a justifiable effort to explain the dramatic decline of startup generation and flow of available investment funding since the peak of the Read More >
Our commitments to help heal, fuel and feed the world
By Stephen Sherwin, Former Chairman of BIO All of us who have chosen careers in biotech began our journey because we passionately believe in the ability of our industry to improve the human condition. For many of us, this means devoting our career to improving the treatment of incurable diseases. For others, this means employing the power of biotech to provide high-quality and healthy food for everyone on this planet. And, for still others it Read More >
